Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1849–1872 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: APOL1-Mediated Kidney Disease
Interventions: AZD2373-Arm 1, AZD2373-Arm 2, Placebo, APOL1 Genotyping Clinical Trial Assay; Combination Product · Device
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 86
States / cities: Alabaster, Alabama • Birmingham, Alabama • Irondale, Alabama + 73 more

Conditions: Sedentary Behavior, Screen Time, Physical Activity, Sleep
Interventions: Device-based feedback, self-monitoring, and education: CORE, Sedentary Screen Time lockout: LOCKOUT, Context-based prompts: TEXT, Earn sedentary screen time through moderate-vigorous physical activity: EARN; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 23 Years to 64 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Tempe, Arizona • San Luis Obispo, California

Conditions: Relapsed/Refractory Large B-cell Lymphoma
Interventions: Cyclophosphamide, Fludarabine, Axicabtagene Ciloleucel, Utomilumab; Drug · Biological
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Palo Alto, California • Santa Monica, California • Tampa, Florida + 2 more

Conditions: Locally Advanced (Inoperable) or Metastatic Breast Cancer
Interventions: Capivasertib, Fulvestrant, Palbociclib, Ribociclib, Abemaciclib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 40
States / cities: Tucson, Arizona • Fountain Valley, California • Glendale, California + 35 more

Conditions: Major Depressive Disorder (MDD), Healthy Adult Volunteer
Interventions: Hot Cognitive Task, Cold cognitive tasks, Structural magnetic resonance imaging (sMRI), Magnetoencephalography imaging (MEG), four self-report forms per the requirement of the NIH Common Data Elements project, Four self-report measures to assess interpersonal functioning, Clinical assessments, ATHF; Behavioral · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 80 Years
Enrollment: 276 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Arlington, Texas • Dallas, Texas

Conditions: Suicide, Surveillance, Mental Health, Substance Use, Depressive Symptoms
Interventions: New Hope (NH), Elders Resilience (ER), Case Management (CM); Behavioral · Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 16 Years to 29 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Whiteriver, Arizona

Conditions: Lung Cancer, Non-Small Cell, Metastatic Squamous Cell Carcinoma, Metastatic Non-Squamous Cell Carcinoma
Interventions: ADXS-503, Pembrolizumab; Drug
Lead sponsor: Advaxis, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 9
States / cities: Duarte, California • Los Angeles, California • Atlanta, Georgia + 6 more

Conditions: Attention Deficit/Hyperactivity Disorder(ADHD), Alcohol Use
Interventions: Ecological Momentary Assessment for ADHD and Substance Use - Intervention Group, Ecological Momentary Assessment for ADHD & Substance Use - Control Group; Device
Lead sponsor: Traci Kennedy; Other
Eligibility: 18 Years to 25 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Osteoporosis
Interventions: Teriparatide, Alendronate, Calcium, Vitamin D3; Drug · Dietary Supplement
Lead sponsor: Helen Hayes Hospital; Other
Eligibility: 45 Years to 85 Years · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: West Haverstraw, New York

Conditions: Type 2 Diabetes
Interventions: AZD0186, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Glendale, California

Conditions: Asthma
Interventions: School-Based Asthma Care for Teens (SB-ACT), Directly Observed Therapy, Asthma Education; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 12 Years to 16 Years
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Menopausal, Dementia
Interventions: PERI-MIND; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 40 Years to 58 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gynecologic Cancer
Interventions: Fitbit, Fitbit + Game + Support from a Teammate; Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Brewer, Maine • Boston, Massachusetts • Providence, Rhode Island

Conditions: Breast Neoplasms
Interventions: Allogeneic GM-CSF-secreting breast cancer vaccine, Trastuzumab, Cyclophosphamide; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Psoriasis
Interventions: Risankizumab, Ustekinumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Birmingham, Alabama • Fountain Valley, California • Sacramento, California + 18 more

Conditions: Epilepsy, Epilepsy Intractable, Seizures, Seizure Disorder, Ketogenic Dieting, Ketosis
Interventions: Betaquik; Dietary Supplement
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rift Valley Fever
Interventions: TSI-GSD 200 RVF Vaccine; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 17 Years and older
Enrollment: 278 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Fort Deterick, Maryland

Conditions: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
Interventions: Entrectinib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 48
States / cities: Phoenix, Arizona • Duarte, California • La Jolla, California + 32 more

Conditions: Cystic Fibrosis, Burkholderia Infections
Interventions: AZLI, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 34
States / cities: Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 31 more

Conditions: Bleeding
Interventions: 60mg edoxaban, 180mg edoxaban, 50 IU/kg Beriplex P/N, 25 IU/kg Beriplex P/N, 10 IU/kg Beriplex P/N; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Immune System Disorder, Healthy Volunteers
Interventions: Belumosudil, UGT1A1 victim drug, P-gp victim drug, OATP1B1/BCRP victim drug; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hepatocellular Carcinoma
Interventions: TheraBionic, Regorafenib; Device · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Primary Central Nervous System Lymphoma
Interventions: Rituximab plus Temozolomide; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: New Haven, Connecticut • Hollywood, Florida • Orlando, Florida + 1 more

Conditions: Healthy
Interventions: PF-04171327, Prednisone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Search by objective public record fields.

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

StandUPTV: Reducing Sedentary Screen Time in Adults

Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression

Southwest Hub for American Indian Youth Suicide Prevention Research

Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer

Smartphone-based Intervention for Young Adults With ADHD

Cyclic Versus Daily Teriparatide on Bone Mass

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

School-based Asthma Care for Teens (SB-ACT)

Development of a Personalized, Psychosocial Intervention for Menopausal Individuals With Elevated Dementia Risk

Step Into Support for Endurance and Strength (SISTERS)

Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for the Treatment of HER-2/Neu-Overexpressing Metastatic Breast Cancer

A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet

Safety and Immunogenicity Study of Rift Valley Fever Vaccine

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation

A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma

Single Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism